Crossover Miracle: How a Novel Glucose-Lowering Drug Became the Respiratory Guardian for COPD Patients
Affiliation: Center of Big Data Research
Imagine the airways transforming into rusted, clogged pipes, making every breath an immense struggle—this is the daily reality for patients suffering from Chronic Obstructive Pulmonary Disease (COPD). When concurrently afflicted with diabetes, the lungs are vulnerable to "acute exacerbations" that strike like severe storms. Such exacerbations not only inflict permanent damage to pulmonary function but also significantly elevate the risk of mortality. Consequently, "preventing exacerbation" has consistently remained the most critical line of defense in safeguarding lung health.
Historically, the medical community relied primarily on inhalers or smoking cessation to protect the lungs. However, a nationwide study in Taiwan utilizing big data has uncovered a cross-disciplinary "guardian": a novel glucose-lowering medication originally indicated for diabetes, known as the "SGLT2 inhibitor" (commonly referred to as a glucose-excreting drug). This medication has demonstrated extraordinary efficacy in protecting the lungs from exacerbations, substantially outperforming traditional "DPP4 inhibitors."
The research team rigorously screened and matched patients from the National Health Insurance Research Database who were concurrently diagnosed with diabetes and COPD between 2017 and 2021. The data revealed that patients taking SGLT2 inhibitors experienced a remarkable 31% reduction in the overall risk of acute exacerbations. Even more encouragingly, the incidence rate of "severe acute exacerbations"—episodes requiring immediate emergency room visits or hospitalizations—was drastically reduced by 65%, and the time to the first exacerbation was successfully delayed by more than twofold. This signifies that patients can effectively minimize the torment of frequent hospital admissions, thereby vastly improving their quality of life. Furthermore, the protective scope of this medication is exceptionally broad. Whether the patients are elderly, male, or have not yet developed concomitant cardiovascular diseases, all can derive significant clinical benefits.
Why does a glucose-lowering drug possess lung-protective properties? Scientists hypothesize that SGLT2 inhibitors not only assist the body in excreting glucose through urine but also reduce the "carbon dioxide exhaust" generated by systemic glucose metabolism, imperceptibly alleviating the ventilatory burden on the lungs. Simultaneously, the drug can mitigate systemic chronic inflammatory responses and decrease the probability of respiratory tract infections such as pneumonia. For this specific cohort of patients with comorbidities, the SGLT2 inhibitor is no longer merely a pill for precise glycemic control; rather, it serves as a robust line of defense silently safeguarding every smooth breath.

Figure 1. The protective mechanism of SGLT2 inhibitors in patients with diabetes accompanied by COPD. By reducing the CO₂ load, mitigating systemic inflammation, and preventing infections, the drug provides a protective shield for the lungs. This mechanism corroborates the research findings that SGLT2 inhibitors can significantly reduce the risk of severe acute exacerbations in patients.
Reference: Ting-Chia Chang, You-Cyuan Liang , Chih-Cheng Lai, Chung-Han Ho , Yi-Chen Chen , Kuang-Ming Liao, Fu-Wen Liang*. Comparison of SGLT2 and DPP4 inhibitors on clinical outcomes in COPD patients with diabetes: A nationwide cohort study. Diabetes Res Clin Pract. 2025 May:223:112122. (SCIE, IF 2025: 4.6, 55/198=27.77% in ENDOCRINOLOGY & METABOLISM)
